Skip to main content
. 2026 Jan 3;18(1):164. doi: 10.3390/cancers18010164
ADC Antibody–Drug Conjugate
DAR Drug–Antibody Ratio
DRF Dose Range Findings
HC Heavy Chain
IP Immunoprecipitation
LC Light Chain
LC-MS Liquid Chromatography–Mass Spectrometry
LP Linker-Payload
MRM Multiple Reaction Monitoring
PD Pharmacodynamics
PK Pharmacokinetics
RP-HPLC Reverse Phase–High-Performance Liquid Chromatography
RTSs Rat Toxicity Studies
SEC-HPLC Size Exclusion Chromatography–High-Performance Liquid Chromatography